U of T-led study finds positive support from parents and clinicians for pediatric cancer pain management app

A recent study led by Assistant Professor Lindsay Jibb of the Lawrence Bloomberg Faculty of Nursing and Scientist at The Hospital for Sick Children (SickKids) found that parents of young children with cancer, along with pediatric cancer clinicians are in favour of an app-based solution that Jibb and her team are creating, to help parents manage their child’s cancer pain at home.

NCCN Senior Director Evelyn Handel Zapata is Named a ‘40 Under 40 in Cancer: Emerging Leader’ for Milestone Work Improving Safe Use of Chemotherapy

Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader; launches new resources for a type of pediatric lymphoma.

NCCN Releases New Resource to Help Families Understand Pediatric Hodgkin Lymphoma, Part of Award-Winning Patient Information Series

The National Comprehensive Cancer Network (NCCN) today announces the publication of NCCN Guidelines for Patients: Hodgkin Lymphoma in Children.

Penn State Health Children’s Hospital, Penn State College of Medicine bring international research consortium to Hershey to strengthen their fight against childhood cancer

Penn State Health and Penn State College of Medicine are strengthening their commitment to curing childhood cancer by bringing Dr. Giselle Saulnier Sholler, an internationally known physician-scientist, and her research consortium to Hershey.

Children’s Hospital Los Angeles: La Mejor Atención Pediátrica en California y la Región del Pacífico de los EE.UU.

CHLA vuelve a ser el hospital pediátrico Nro. 1 en su estado natal de California y en el Pacífico de los Estados Unidos, una región que incluye todos los estados a lo largo de la Costa Oeste, incluido Hawái. CHLA también ascendió al Nro. 7 en general a nivel nacional en el Cuadro de Honor de los Mejores Hospitales Infantiles de este año, el estándar de oro de los principales destinos para la atención pediátrica, y está clasificado a nivel nacional en las 10 subespecialidades pediátricas evaluadas, incluido el Nro. 2 en los EE. UU. en ortopedia, Nro. 3 en cáncer y Nro. 5 en gastroenterología y cirugía GI.

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma

In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children’s Cancers

NCCN is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.

Mount Sinai Researchers Find New, Safer Treatment for Serious Side Effect of Bone Marrow Transplant

Researchers at The Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than the standard of care for a serious, and sometimes fatal, side effect of bone marrow transplant in cancer patients. Results from a phase 2 clinical trial were presented at the annual meeting of the American Society of Hematology (ASH) in December.

SAFER Ukraine provides a blueprint for responding to global health crises

Russia’s invasion of Ukraine created a dire situation for children with cancer and blood disorders. In response, the St. Jude Global initiative of St. Jude Children’s Research Hospital banded together with international partners and formed SAFER Ukraine. An account appears in The Lancet Haematology.

Dana-Farber/Boston Children’s again named top pediatric cancer program

U.S. News &World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center #1 in the nation in its 2022-23 Best Children’s Hospitals report. Dana-Farber/Boston Children’s has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking’s inception, earning more #1 rankings than any other program.

Children’s Hospital Los Angeles: 美国加州和太平洋地区最好的儿童护理机构

《美国新闻与世界报道》再次将 CHLA 评为其本州加利福尼亚州和美国太平洋地区(包括阿拉斯加州、加利福尼亚州、夏威夷州、俄勒冈州和华盛顿州)的最佳儿童医院。CHLA 还连续 14 年(自该排名诞生以来从未缺席)入选该刊年度“最佳儿童医院榜”——美国领先儿科机构权威榜单——最终名列第 8 位。

Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Cure 10 Years Later

Ten years ago, Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so rapidly that she was ineligible for a bone marrow transplant to treat it. Her family came to CHOP in the hopes that Dr. Stephan Grupp, a pioneer in the field of cellular immunotherapy, could provide the miracle they were looking for.

Combining Two ‘Old Therapies’ Packs a Powerful Punch Against Pediatric Brain Tumors

Researchers at Johns Hopkins Medicine and Italy’s Catholic University of the Sacred Heart medical school have provided solid evidence that copper, the first metal used medicinally, may now have a new role — helping save children from a devastating central nervous system cancer known as medulloblastoma.

CHOP Researchers Develop a New Class of CAR-T Cells that Target Previously Untargetable Cancer Drivers

In a breakthrough for the treatment of aggressive solid cancers, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach. Using the power of large data sets and advanced computational approaches, the researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with “peptide-centric” chimeric antigen receptors (PC-CARs), a new class of engineered T cells, stimulating an immune response that eradicates tumors.

New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children

National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research. NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.

CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors

In a large study of pediatric cancer patients, researchers from Children’s Hospital of Philadelphia (CHOP) have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors. The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.

Studying Patterns of Relapse in Pediatric Hodgkin Lymphoma using a Response-Based Therapy Approach

Recent research from Rutgers Cancer Institute of New Jersey expert as part of a phase 3 study from the Children’s Oncology Group explores response-based consolidation with modern radiation therapy as safe and effective standard of care for pediatric Hodgkin lymphoma patients. This work is being presented at the Annual Meeting of the American Society for Radiation Oncology (ASTRO) this week.

New Guidelines for Maximizing Cures and Minimizing Side Effects in Children with Hodgkin Lymphoma

The National Comprehensive Cancer Network announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma, one of the most curable forms of pediatric cancer. They synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment.